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Recent advances in the analysis of RNA sequencing data have shown that pseudogenes 
are highly specific markers of cell identity and can be used as diagnostic and prognostic 
markers. Furthermore, genetically engineered mouse models have recently provided 
compelling support for a causal link between altered pseudogene expression and can-
cer. In this review, we discuss the most recent milestones reached in the pseudogene 
field and the use of pseudogenes as cancer classifiers.
Keywords: pseudogenes, cancer, diagnostic markers, prognostic markers, ceRNAs, animal models of cancer, 
mutagenic factors
1. introduction
Since their discovery, pseudogenes have been neglected and considered bad copies of coding genes 
that have lost their coding potential and are void of function. Recently, it has emerged that pseu-
dogenes represent a conspicuous part of the human transcriptome and proteome, as thousands of 
them are transcribed and hundreds are also translated (1, 2). Furthermore, it has been demonstrated 
that pseudogenes exert important coding-dependent and coding-independent functions that are 
involved in complex regulatory networks. It has also become apparent that pseudogenes contribute 
to the role that the non-coding genome plays in normal physiology as well as, when altered, in human 
disease. On this basis, pseudogenes are currently ranked among the classes of long non-coding RNAs 
(lncRNAs) (3–5).
While the origin of pseudogenes in the human genome and their role during evolution and 
speciation have been extensively studied for years (6–8), most of the known pseudogene functions 
have been discovered quite recently in the context of human cancer, where pseudogenic DNA, RNA, 
and peptides/proteins have been shown to exert parental gene-related and unrelated functions (for 
an overview, please refer to Figure 1).
In this review, we focus on recent advances in the field of pseudogenes in cancer, namely the 
establishment of their utility as diagnostic and prognostic factors, as well as the formal proof of their 
causal link with tumorigenesis, which has been established in genetically engineered mouse models.
2. Pseudogene Detection
Transcribed pseudogenes can be detected using RNA sequencing (RNA-seq), microarrays, and 
real-time PCR.
RNA sequencing (RNA-seq) allows to obtain an accurate assessment of all the pseudogene 
 species  present in a transcriptome and of their relative abundance. Crucially, it is also the only tech-
nique among the three that allows the discovery of new pseudogenes and hence it can provide the 
knowledge on which the other two techniques are built. However, RNA-seq costs are still quite high 
and ad hoc bioinformatic pipelines are required for data analyses. Fortunately, after the pioneering 
example published in 2012 by Kalyana-Sundaram et al. (9), quite a few pipelines of this sort have 
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FiGURe 1 | An overview of pseudogene functions. (A–e) Parental gene-related functions of pseudogenes (left). (A) Pseudogenes and parental genes can 
exchange genomic DNA through gene conversion or homologous recombination. The pseudogene promoter can also affect the transcription of the parental gene. 
(B) Pseudogene RNA transcribed in sense and antisense orientation can affect the transcription of the parental gene at the epigenetic level. (C) Pseudogene sense 
and antisense transcripts can form a double-stranded RNA that is cleaved into endogenous siRNAs. In turn, esiRNAs affect the parental gene expression at the 
post-transcriptional level. (D) Pseudogene RNA transcribed in sense orientation can compete with parental mRNA for the binding of microRNAs, RNA-binding 
proteins (RBPs), or the translational machinery. (e) Pseudogene proteins can be highly homologous to parental proteins, but be expressed in a different context 
(tissue, cellular compartment, pathophysiological condition). They can also carry gain-of-function mutations. Finally, they may affect the function of the parental 
proteins even if they are not fully functional. (F–H) Parental gene-unrelated functions of pseudogenes (center). (F) The de novo acquisition of new exons at either side 
(processed pseudogenes) or in the middle (non-processed pseudogenes) of their genomic sequence contributes to distinguishing the sequence, and hence the 
function, of pseudogenes compared to that of their parental genes. (G) Pseudogene RNA transcribed in antisense orientation can affect the stability of the sense 
pseudogenic transcript. (H) Pseudogene RNAs can be matured into microRNAs or translated into antigenic peptides. (i–K) Parental gene-unrelated functions of 
pseudogenes (right). (i) The “landing” of a processed pseudogene within other genes can produce several different scenarios. If the insertion site is an upstream 
intron, then the processed pseudogene will be cotranscribed with its host gene as a non-coding fusion transcript. If a protein is eventually translated, then it will most 
likely be short and contain only the pseudogene sequence. Pseudogenes inserted in upstream introns can also affect the transcription of the host gene by epigenetic 
silencing. If the insertion site is a more downstream intron, then the processed pseudogene will be cotranscribed with its host gene as a coding fusion transcript and 
the translated protein will be a chimera that is composed of both the gene and the pseudogene sequence. If the insertion site is in a 3′-UTR-expressing exon, then 
the fusion transcript will display an altered post-transcriptional regulation. If the pseudogene lands in a coding exon, the result will be insertional mutagenesis that will 
likely abrogate the expression of the host gene. (J) Pseudogenes and adjacent genes can be transcribed into joint read-through transcripts and translated into 
chimerical proteins. (K) Pseudogene RNAs working as source of esiRNAs or as sponges can also affect other unrelated genes besides the parental genes.  
The DNA/RNA/protein of a representative pseudogene, parental gene, and unrelated gene are shown in red, blue, and green, respectively. For a detailed overview  
of parental gene-related and unrelated functions of pseudogenes, please refer to Ref. (7) with updates reported in Ref. (9–18). For a list of the pseudogenes that 
function as sponges for microRNAs (a.k.a. competing endogenous RNAs) in cancer, please refer to Table 1.
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been published and have allowed for the definition of the 
pseudogene profile in multiple cancer types, including bladder 
cancer, breast cancer, cervical cancer, colorectal cancer, endo-
metrioid carcinoma, gastric cancer, glioma, kidney cancer, 
lung cancer, melanoma, ovarian cancer, pancreatic cancer, and 
prostate cancer (5, 10, 19–22).
Microarrays, which offer the advantage of lower costs and 
easier data analysis compared to RNA-seq, are in fact rarely used 
for the purpose of pseudogene detection, unless they are designed 
to contain probes that bind specifically to pseudogenes and do 
not cross-bind to parental genes (23–25).
Finally, real-time PCR stands out for its low cost, high sensitiv-
ity, and high specificity. It is also the only technique among the 
three that is feasible to use routinely in the laboratory for a diag-
nostic or prognostic test. However, extreme care has to be taken 
in order to ensure that it is the pseudogene to be indeed amplified 
and the inadvertent amplification of the very similar parental gene 
is avoided. Multiple programs should be used in order to design 
primer pairs that recognize regions of low sequence similarity. It 
is also advisable to check that the amplified product is unique and 
that its size and sequence are the expected ones.
In the case that the pseudogene expression is assessed from the 
serum/plasma, it is also important to choose the right normaliza-
tion control. Ideally, multiple genes need to be amplified by real 
time beforehand and then the one showing less variation among 
the samples under study should be chosen as control (26).
3. Pseudogenes as Diagnostic Markers in 
Human Cancer
Examples also exist that highlight the diagnostic power of specific 
pseudogenes. In gastric cancer, the levels of SUMO1P3 pseudo-
gene are up-regulated and can be used to differentiate patients 
with cancer from patients with benign gastric disease (27). 
Compared to healthy controls, patients with gastric cancer are 
also characterized by lower serum levels of PTENP1 pseudogene, 
and such down-regulation, together with that shown by two 
additional lncRNAs (CUDR and LSINCT-5), has high diagnostic 
power [area under the curve (AUC) >0.8] (26). Analogously, 
hepatocellular carcinoma (HCC) patients are characterized by 
lower serum levels of the INTS6P1 pseudogene compared to 
healthy individuals, and the diagnostic power of the pseudogene 
appears to be equal if not higher than that of alpha-fetoprotein, 
the most commonly used diagnostic biomarker for HCC (28).
Thanks to the development of the bioinformatic pipelines 
mentioned in Section 2 above, we have been able to fully 
appreciate the ability of aberrant pseudogenes expression to 
distinguish cancer tissues from normal tissues as well as one 
cancer subtype from another (9, 19, 21). Through the analysis 
of the RNA-seq data of 293 samples belonging to 13 cancer and 
normal tissue types, Kalyana-Sundaram and colleagues identified 
218 pseudogenes that are expressed only in cancer samples and 
not in the correspondent benign tissues (9). Among them, the 
authors showed that 40 pseudogenes are cancer type-specific, 
being expressed only in a single cancer type (i.e., breast cancer, 
chronic lymphocytic leukemia, gastric cancer, pancreatic cancer, 
and prostate cancer). Finally, they focused on two pseudogenes 
with cancer subtype-specific expression: ATP8A2-pg (expressed 
in luminal but not in basal breast cancer samples) and CXADR-pg 
[mainly expressed in prostate cancer samples that do not carry an 
ETS fusion gene (29)].
Along a similar line, the analysis of RNA-seq data of 2,808 
samples belonging to seven different cancer types [breast invasive 
carcinoma (BRCA), glioblastoma multiforme (GBM), kidney 
renal clear cell carcinoma (KIRC), lung squamous cell carcinoma 
(LUSC), ovarian serous cystadenocarcinoma (OV), colorectal 
carcinoma (CRC), and uterine corpus endometrioid carcinoma 
(UCEC)] has allowed Han and colleagues (19) to identify a 
plethora of pseudogenes that display subtype-specific expression. 
Namely, 48 in UCEC (endometrioid vs. serous), 138 in LUSC 
(basal, classical, primitive, and secretory), 71 in GBM (classical, 
mesenchymal, neural, and proneural), and 547 in BRCA (PAM50 
subtypes: luminal A, luminal B, basal-like, Her2-enriched, and 
normal-like). Interestingly, this analysis confirmed that the 
expression of ATP8A2-pg is virtually absent in the basal-like breast 
cancer subtype. Furthermore, it showed that the pseudogene 
profile of UCEC samples can be used to accurately distinguish 
between the endometrioid and serous subtypes (AUC >0.9).
4. Pseudogenes as Prognostic Markers in 
Human Cancer
Once the correct cancer types and subtypes have been diagnosed, 
the choice of the best treatment option is further supported by 
the ability to foresee the prognosis. Recently, several examples 
have been reported that show how pseudogenes, besides being 
accurate diagnostic markers, are also valuable prognostic mark-
ers that can be used to stratify cancer patients on the basis of their 
life expectancy.
As an example, the PTENP1 pseudogene functions as a ceRNA 
for its oncosuppressive parental gene PTEN (see below), and in 
clear cell renal cell carcinoma it has been shown that patients 
who do not express PTENP1 display a shorter overall survival 
compared to those that do express PTENP1 (30).
The E2F3P1 pseudogene can present a guanine or an adenine 
at the rs9909601 SNP, and in HCC the overall survival of the 
patients carrying the GA/AA allele has been shown to be better 
than that of the patients carrying the GG allele (31).
The OCT4 gene has multiple pseudogenes, which are prefer-
entially expressed instead of the parental gene in human cancer 
cells (7, 11). Similar to what has been reported above for E2F3P1, 
OCT4-pg1 (also known as POU5F1P1 or POU5F1B) is a poly-
morphic pseudogene that presents an A or a G nucleotide at the 
rs10505477 SNP. Interestingly, gastric cancer patients who have 
undergone cisplatin-based chemotherapy and carry the GA/AA 
genotype have a poorer overall survival compared to those who 
have undergone the same treatment, but instead carry the GG 
genotype (32). Furthermore, Hayashi and colleagues (33) have 
shown that in gastric cancer OCT4-pg1 is overexpressed due to a 
genomic amplification (the OCT4-pg1 gene is located on chromo-
some 8q24 and is coamplified with its neighbor c-MYC) and that 
the OCT4-pg1 protein exerts an oncogenic role by promoting 
proliferation and angiogenesis while inhibiting apoptosis. In 
addition, the authors have observed that in stage IV patients, 
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OCT4-pg1 amplification is associated with a decreased overall 
survival.
Another OCT4 pseudogene, namely OCT4-pg4, promotes 
HCC cell proliferation by competing for miR-145 and hence 
sustaining the expression of its parental gene OCT4 (see below for 
a ceRNA role of pseudogenes). Furthermore, it has been shown 
that OCT4-pg4 expression levels stratify HCC patients according 
to their disease stage and overall survival, being that high expres-
sors have a worse prognosis than low expressors (34).
Besides specific pseudogenes, a prognostic value has also 
been attributed to pseudogene signatures. Beginning with 183 
glioma datasets belonging to the Chinese Glioma Genome Atlas 
(CGGA), Gao and colleagues (20) looked for pseudogenes that 
are associated with overall survival. In doing so, they identified 
a signature composed of six pseudogenes: SP3P, ANXA2P3, 
PTTG3P, LPAL2, CLCA3P, and TDH. In patients with shorter 
survival, the levels of the first five resulted higher, while those of 
TDH resulted lower. Next, the authors developed a formula that 
attributes a risk score to each glioma patient and is based on the 
cumulative expression levels of these six pseudogenes. By using 
this formula, they were able to classify CGGA patients accord-
ing to their overall survival (patients with a high-risk score have 
a poorer prognosis than patients with a low-risk score). These 
findings were further validated in a different cohort of 350 glioma 
cases belonging to the Repository of Molecular Brain Neoplasia 
Data (Rembrandt) dataset.
In the same study mentioned in Section 3 above, the authors 
assessed the ability of pseudogenes to stratify KIRC patients 
according to their overall survival (19). This cancer type was cho-
sen because, as of today, it is among the few that still lack reliable 
prognostic markers. By following a reverse approach compared to 
the one described in the paragraph above, the authors analyzed 
the expression profile of 446 KIRC samples and noticed that 
500 pseudogenes are able to sort them into two distinct clusters. 
Interestingly, they observed that patients belonging to cluster 1 
have a better prognosis than patients belonging to cluster 2 (19). 
A formula was developed that attributes a risk score to each KIRC 
patient and is based on the pseudogene expression levels as well 
as on other clinical variables. Interestingly, low-risk and high-risk 
patients can be stratified according to their overall survival using 
clinical variables alone. However, the low–medium risk group 
and the medium–high risk group can be distinguished only by 
the combination of clinical data and risk score based on the 
pseudogene expression levels. These results represent a paradig-
matic example of the added value that pseudogenes can bring to 
prognostic predictions.
Finally, in the recently reported study by Ganapathi and 
colleagues (35), 21 primary and 24 recurrent high-grade serous 
ovarian cancer (HGSOC) samples were subjected to RNA-seq 
analysis. Twenty-one protein-coding genes and one non-coding 
gene were found to be differentially expressed between the two 
sample groups. The differential expression of the non-coding 
gene (the previously uncharacterized SLC6A10P pseudogene) 
was confirmed by real-time PCR in a larger validation cohort 
composed of 71 primary and 39 recurrent HGSOCs. Furthermore, 
low levels of SLC6A10P were found to be associated with longer 
time to progression, especially if considered together with high 
levels of one among the differentially expressed protein-coding 
genes (COL2A1) (35). This article offers a paradigmatic example 
of the ability of high-throughput techniques such as RNA-seq to 
point toward novel protein-coding and non-coding genes that 
not only contribute to our understanding of tumor pathogenesis 
but can also be exploited as useful biomarkers.
5. Pseudogenes as Mutagenic Factors
There are multiple lines of evidence in support of a causal link 
between altered pseudogene expression and the pathogenesis of 
human cancer (7, 36). First, pseudogenes often show cancer-spe-
cific deregulated expression, for example in the case of the OCT4 
and NANOG pseudogenes, which are aberrantly expressed in 
cancer cells instead of their parental genes (7, 11, 18, 37). Second, 
similar to protein-coding genes, pseudogenes can undergo chro-
mosomal rearrangements, amplification, deletion, and epigenetic 
silencing. HMGIY pseudogenes have been shown to be affected 
by chromosomal rearrangements in benign human tumors (38). 
PTENP1, the processed pseudogene of PTEN phosphatase, is a 
paradigmatic example of an oncosuppressive pseudogene that 
is deleted or hypermethylated in human cancer (23, 30, 39, 40). 
Conversely, as mentioned in the Section 4 above, the oncogenic 
OCT4-pg1 is coamplified with c-MYC (33). Third, it has been 
reported that several variations in the sequence of pseudogenes 
such as those of PARP and CK2 can predispose to cancer (7).
Recently, a new and well-supported line of evidence for an 
oncogenic role of pseudogenes has been described. Cooke et al. 
(12) have shown that processed pseudogenes behave as muta-
genic factors and impact the transcriptional landscape of the 
cells. Processed pseudogenes evolve from a retrotransposition 
event: the cDNA of the parental gene is retrotranscribed into 
DNA and is inserted randomly in the genome. As a consequence, 
pseudogenes do not contain introns, are located in a different 
region of the genome, and are subjected to a different regulation 
compared to that of their parental genes (7). The authors ana-
lyzed genome sequencing data of 660 cancer samples spanning 
18 tumor types and identified 42 processed pseudogenes that 
are acquired somatically (namely, present in the cancerous tissue 
and absent in the matched normal tissue). These pseudogenes 
are mostly derived from highly expressed transcripts by LINE 
retrotransposition and are most frequently found in two cancer 
types: non-small cell lung cancer and colorectal cancer. In order 
to assess the consequences of pseudogenes retrotransposition on 
the expression of the pseudogenes themselves and of their host 
genes, the authors performed RNA sequencing on five samples 
in which they had identified 16 somatically acquired processed 
pseudogenes. Among them, 10 were found to have landed in 
intergenic regions, three in introns and three in exons. The last 
group of pseudogenes was further analyzed in light of the possible 
deleterious consequences on the expression of the host genes. The 
insertion of the KRT6A pseudogene in the 3′-UTR-expressing 
exon of the MLL gene was shown to cause the transcription 
of a fusion RNA, in which the 3′-UTR of MLL is replaced by 
the pseudogenic sequence. This, in turn, implicates that all the 
3′-UTR-mediated post-transcriptional regulation of MLL expres-
sion is aberrantly lost. Analogously, the insertion of KIF18A 
TABLe 1 | Pseudogenes that function as ceRNAs for their parental genes or other genes in cancer.
Pseudogene Parental gene Other genes Shared microRNAs Context Reference
Oncosuppressive pseudogenes
PTENP1 PTEN miR-17, 19, 21, 26, and 214 families Prostate cancer
Melanoma
Endometrial cancer
ccRCC
Hepatocellular carcinoma
Gastric cancer
(23)
(39)
(44)
(15)
(30)
(45)
(40)
PTENP1 HRASLS5 miR-135b Breast cancer (13)
TUSC2P TUSC2 miR-17, 93, 299-3p, 520a, 608, and 661 Breast cancer (46)
INTS6P1 INTS6 miR-17-5p Hepatocellular carcinoma (47)
Oncogenic pseudogenes
OCT4-pg4 OCT4 miR-145 Hepatocellular carcinoma (34)
OCT4-pg5 OCT4 miR-145 Endometrial carcinoma (48)
HMGA1P6 HMGA1 miR-15, 16, 214, and 761 Thyroid carcinoma (49)
HMGA1P7 Pituitary tumors (50)
CYP4Z2P CYP4Z1 miR-125a-3p, 197, 204, 211, and 1226 Breast cancer (51)
BRAFP1 BRAF miR-30a, 182, 590, and 876 DLBCL (52)
Braf-rs1 Braf miR-134, 543, and 653 Diffuse large B-cell 
lymphoma
(52)
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pseudogene in the 3′-UTR-expressing exon of two overlapping 
transcripts (KIAA1967 and BIN3) causes the transcription of two 
hybrid mRNAs in which the pseudogene sequence replaces that 
of the 3′-UTR of the host gene. Even more strikingly, the authors 
report that the landing of PTPN12 pseudogene in the first exon 
of MGA, which is a likely oncosuppressor gene, causes an 8 kb 
deletion. This deletion spans the first exon itself, as well as the 
promoter region, and is ultimately responsible for the abrogation 
of MGA expression (12).
6. Pseudogenes as ceRNAs in Human 
Cancer
Pseudogene RNAs can behave as competing endogenous RNAs 
(ceRNAs). Because of their sequence similarity, the pseudogenes 
share multiple microRNA recognition elements (MREs) with 
their parental genes and can compete for the binding of com-
mon microRNA molecules (Figure  1D). As a consequence, 
pseudogenes sustain the expression of their parental genes and 
hence can acquire oncogenic or oncosuppressive functions when 
deregulated. For a comprehensive overview of ceRNA networks 
discovered in human cancer, both those that involve pseudogenes 
and other non-coding RNA classes, as well as those that involve 
protein-coding genes, please refer to Ref. (41–43) (these review 
articles also contain a detailed description of the rules that govern 
this class of regulatory networks and of the tools that are currently 
available to predict them).
The processed pseudogene PTENP1 was the first ceRNA to be 
discovered in human cancer cells (23, 41). Since the discovery of 
PTENP1, the list of oncogenic and oncosuppressive pseudogenes 
that act as ceRNAs for their parental genes has been greatly 
expanded (those that have been characterized up to July 2015 are 
listed in Table 1). Furthermore, a multitude of pseudogene/paren-
tal gene pairs that show a positive correlation in their expression 
levels (which is strongly suggestive of ceRNA-based interactions) 
have emerged from the analysis of RNA-seq data of normal tissues 
(10) as well as from cancer cells such as breast and KIRC (19, 21).
Additionally, it has been shown that pseudogenes can act 
as ceRNAs not only for their parental genes but also for other 
genes (Figure 1K and Table 1). This is because the microRNAs 
that they share with their parental genes have also other targets 
and because they can be targeted by additional microRNAs. 
For example, PTENP1 has been shown to exert oncosuppres-
sive activity in prostate cancer cells that carry a deletion of the 
parental gene PTEN (23). Similarly, in breast cancer cells, it 
has been shown that PTENP1 modulates the expression levels 
of HRASLS5 (HRAS-like suppressor family, member 5) mRNA 
through the binding of miR-135b, a microRNA that has not been 
yet reported as PTEN-targeting (13).
Unitary pseudogenes represent an ultimate example of the 
ability of pseudogenes to exert ceRNA-based functions that are 
parental gene independent. The pseudogenes belonging to this 
class do not have parental counterparts because they derive from 
the progressive acquisition of mutations in protein-coding genes 
(7). Interestingly, Marques et al. (53) have shown that the func-
tion of unitary pseudogenes as ceRNAs can outlive their protein 
coding capacity, as indicated by the fact that the sequence of their 
MREs is more subjected to selective pressure than that of their 
coding sequence.
Lastly, besides the one pseudogene/one protein-coding gene 
cases, it is emerging that pseudogene-based ceRNA networks 
are extremely broad and pervade the cellular transcriptome as a 
whole. Furthermore, it has been shown that the loss or dysregu-
lation of such networks is among the hallmarks of cancer cells 
compared to normal cells (13).
7. Animal Models of Pseudogenic ceRNAs
Besides the lines of evidence described in Section 5, formal 
proof of the causal link existing between pseudogenes and the 
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pathogenesis of human cancer has recently come from genetically 
engineered mouse models (49, 52).
The article by Karreth et al. (52) focused on Braf-rs1, which is 
the processed pseudogene of the mouse Braf kinase, and shares 
53 microRNA families with its parental gene (if both the cod-
ing sequence and the 3′-UTR are considered). This observation 
prompted the authors to evaluate if the pseudogene functions as 
a ceRNA. Indeed, they found that the overexpression of Braf-rs1 
in mouse NIH3T3 cells causes the up-regulation of Braf, the 
hyperactivation of the Erk pathway and, as a consequence, an 
increase in cell growth. Furthermore, the authors show that these 
effects are abolished when Braf-rs1 is overexpressed in mouse 
cells that lack Dicer or that lack the parental gene (Braf KO cells), 
which suggests that the availability of mature microRNAs and 
the expression of Braf are required by Braf-rs1 in order to exert 
its activity. Finally, the authors identified three microRNAs (miR-
134, miR-543, and miR-653) as Braf-rs1 and Braf-targeting and, 
by mutagenizing their MREs on Braf mRNA, proved that they are 
the mediators of the protective effects exerted by the pseudogene 
on the parental gene.
Next, the authors sought to investigate the consequences of 
Braf-rs1 overexpression in vivo. To this end, a TRE-BPS transgenic 
mouse line, in which the ubiquitous expression of Braf-rs1 is under 
the control of a doxycycline (dox)-inducible Tet-response element 
(TRE), was generated. This line was crossed with the CAG-rtTA 
line, and the compound transgenic animals were placed on a dox-
containing diet at 3 weeks of age. The effects of the induction of 
Braf-rs1 expression were dramatic: after approximately 4 months 
of treatment, the mice started to die and their median survival 
was as short as 400 days. Moribund mice were characterized by 
splenomegaly and enlarged lymph nodes, all symptoms that an 
in-depth flow cytometric analysis revealed to be the result of an 
aggressive form of diffuse large B-cell lymphoma (DLBCL).
Braf-rs1-induced lymphomas were further characterized in 
multiple ways. First, lymphoma cells obtained from the spleen of 
TRE-BPS/CAG-rtTA mice were transplanted into immunocom-
promised NSG mice, where they were shown to cause spleno-
megaly and to infiltrate all of the tested organs, which indicates 
that they are transplantable and highly aggressive. Furthermore, 
if doxycycline was removed once the splenomegaly became 
apparent, the lymphomas largely regressed, indicating that 
the tumors are markedly addicted to Braf-rs1, and its aberrant 
expression is required for tumor maintenance. Second, histologi-
cal analyses proved that, consistent with the ceRNA hypothesis, 
Braf-rs1-driven tumors are indeed characterized by increased 
Braf and pErk levels. Furthermore, when transplanted NSG mice 
were treated with a Mek inhibitor, a marked impairment of the 
ability of lymphoma cells to infiltrate other organs was observed, 
which indicates that the tumors are addicted to Braf-rs1 because 
they are addicted to the Erk pathway. Finally, the comparison 
of three distinct transgenic lines (TRE-BPS, TRE-BPSCDS, and 
TRE-BPS3′-UTR) allowed to establish that the aberrant expression 
of the 3′-UTR of Braf-rs1 is sufficient to cause an increase in Braf 
levels, the hyperactivation of the Erk pathway, and a phenotype 
that is very similar to that caused by full-length Braf-rs1. On the 
contrary, the overexpression of Braf-rs1 coding sequence does 
not cause a marked increase in Braf levels and induces a milder 
phenotype. These results provide further confirmation that 
Braf-rs1 is a non-coding ceRNA that exerts an oncogenic function 
by increasing Braf levels.
These genetically engineered mouse models represent a proof 
of principle that aberrantly expressed pseudogenes are necessary 
and sufficient to cause cancer by working as ceRNAs for their 
oncogenic parental genes. Furthermore, even if the study is based 
on the mouse Braf pseudogene, it is of relevance to human cancer 
for two reasons.
On the one hand, in the same study, Karreth et al. (52) show 
that BRAFP1, the processed pseudogene of human BRAF, is 
involved in a ceRNA-based relationship with its parental gene as 
well and, for this reason, has oncogenic potential. The microRNA 
families shared between BRAF and BRAFP1 were found to be 40, 
while miR-30a, miR-182, miR-590, and miR-876 were formally 
demonstrated as BRAF and BRAFP1-targeting. In addition, 
BRAFP1 genomic locus was found amplified in the vast majority 
of cancer types featured in TCGA, including DLBCL, where, as 
expected by ceRNA partners, BRAFP1 and BRAF expression 
levels show a positive correlation. In light of this correlation, and 
of the mouse phenotype described above, DLBCL cell lines were 
chosen for a further examination of the ceRNA-based effects of 
BRAFP1 on BRAF. Analogously to the effects exerted by Braf-rs1 
overexpression on Braf (see above), BRAFP1 overexpression was 
shown to exert a protective role on BRAF levels. Conversely, the 
down-regulation of BRAFP1 by shRNA caused a reduction in 
BRAF and pERK levels and was accompanied by a decrease in 
cell proliferation.
On the other hand, it has been recently shown that human 
BRAF exists as two transcript variants, which differ in their 3′-
UTRs (54). The canonical variant, which carries the reference 
3′-UTR reported in all the databases, is up to 0.6 kb long and 
is highly homologous to the 3′-UTR of BRAFP1 pseudogene 
[>90% sequence identity, as shown in (54)], while it is com-
pletely unrelated with the 3′-UTR of mouse Braf. Conversely, the 
X1 3′-UTR variant, which differs from the canonical in length 
(up to 7 kb) and in sequence (it is derived from the alternative 
splicing of an extra 19th BRAF exon), is highly homologous 
to mouse Braf 3′-UTR (84% sequence identity, according to 
https://blast.ncbi.nlm/). This in turn means that, although only 
the canonical BRAF can benefit from the protective effects of 
BRAFP1, total BRAF levels may be subjected to the regulation 
not only of the canonical BRAF-targeting microRNAs but also 
of the mouse Braf-targeting microRNAs. Interestingly, among 
the 191 MREs (for 100 microRNA families) that are predicted 
along the mouse Braf 3′-UTR according to Karreth et al. (52), 
74 MREs (for 58 microRNA families) are also present in the 
3′-UTR of human BRAF-X1 (XM_005250045.1) (Table S1 in 
Supplementary Material).
Together these results support the notion that, analogously 
to PTEN tumor suppressor (41), also BRAF, with its transcript 
variants and its pseudogenes, is under tight microRNA-mediated 
regulation and is likely involved in complex ceRNA-based net-
works. This in turn suggests that at the basis of the oncogenic 
potential of such a powerful protein kinase, there might be not 
only the widely known and extensively studied mutation at the 
Val600 residue but also an aberrant gene expression (55).
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8. Future Perspectives: Pseudogenes as 
Cancer Classifiers
Personalized medicine in cancer treatment is based on the 
assumption that every person harbors a unique variation of the 
human genome in the cancer that he/she develops and should be 
treated accordingly. Thus, in order for a personalized treatment to 
be effective, it is crucial to achieve a detailed classification of the 
cancer genome and epigenome. To this end, a classification solely 
based on the tissue of origin and on pathological features has 
shown its limitations. Conversely, large-scale projects that have 
merged the output of multiple omics techniques (whole-exome 
sequencing, DNA copy number variations, DNA methylation, 
mRNA-seq, microRNA-seq, and proteomics) have shown the 
power of a classification based on molecular alterations. Such an 
approach allows the subdivision of virtually every cancer type into 
multiple subtypes and offers guidance in the treatment of each 
patient with the drug or drug combination that has the highest 
chance to be effective. Furthermore, it shows that molecular level 
similarities exist among cancer types of different tissue of origin 
and offers the rationale for proposing the use of non-standard 
therapeutic strategies (5, 56).
Within this scenario, and in light of the fact that the diagnostic 
and prognostic power of pseudogenes is very high [in some cases 
even higher than that of microRNAs and mRNAs (19)], it is 
not surprising that it has been suggested to include RNA-seq of 
pseudogenes and, in more general terms, of lncRNAs, among the 
“omics” that are used to perform molecular classifications (57). 
The possibility to exploit such accurate markers of cell identity 
could represent a crucial refinement and a further step toward 
an effective personalized medicine. If this is the case, the rescue 
of the pseudogenome from the genetic junk will be complete 
and hopefully will pave the way for the establishment of the 
causal link existing between other classes of non-coding RNAs 
and human cancer.
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